Accumulation of intestinal tissue 3-deoxyglucosone attenuated GLP-1 secretion and its insulinotropic effect in rats

Diabetology and Metabolic Syndrome

Volumn 8, Issue 1, 2016, Pages

  Zhang, Lurong ^a   Song, Xiudao ^a   Zhou, Liang ^a   Liang, Guoqiang ^a   Xu, Heng ^a   Wang, Fei ^a   Huang, Fei ^a   Jiang, Guorong ^a  

^a Suzhou Hospital of Traditional Chinese Medicine   (China)

Author keywords

3 Deoxyglucosone; Glucagon like peptide 1; Impaired glucose regulation; Insulinotropic; Type 2 diabetes mellitus

Indexed keywords

3 DEOXYGLUCOSONE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL M5;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; COLON; CONTROLLED STUDY; DIET RESTRICTION; DUODENUM; ENZYME ACTIVITY; GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; INTESTINAL TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

EID: 85000613599     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-016-0194-9     Document Type: Article

References (48)

1. Parillo M, Riccardi G. Diet composition and the risk of type 2 diabetes: epidemiological and clinical evidence. Br J Nutr. 2004;92:7-19.
2. Hu FB, Van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia. 2001;44:805-17.
3. Popkin BM. The nutrition transition: an overview of world patterns of change. Nutr Rev. 2004;62(suppl 2):S140-3.
4. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514:181-6.
5. Maessen DE, Hanssen NM, Scheijen JL, van der Kallen CJ, van Greevenbroek MM, Stehouwer CD, et al. Post-glucose load plasma α-dicarbonyl concentrations are increased in individuals with impaired glucose metabolism and type 2 diabetes: the CODAM study. Diabetes Care. 2015;38:913-20.
6. Jiang G, Zhang L, Ji Q, Wang F, Xu H, Huang F, et al. Accumulation of plasma 3-deoxyglucosone impaired glucose regulation in Chinese seniors: implication for senile diabetes? Diabetes Metab Syndr. 2002;6:140-5.
7. Dhar A, Desai KM, Wu L. Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. Br J Pharmacol. 2010;159:166-75.
8. Miele C, Riboulet A, Maitan MA, Oriente F, Romano C, Formisano P, et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biol Chem. 2003;278:47376-87.
9. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol. 2011;7:526-39.
10. Degen J, Hellwig M, Henle T. 1,2-Dicarbonyl compounds in commonly consumed foods. J Agric Food Chem. 2012;60:7071-9.
11. Niwa T. 3-Deoxyglucosone: metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl. 1999;731:23-36.
12. Sakiyama H, Takahashi M, Yamamoto T, Teshima T, Lee SH, Miyamoto Y, et al. The internalization and metabolism of 3-deoxyglucosone in human umbilical vein endothelial cells. J Biochem. 2006;139:245-53.
13. Liang G, Wang F, Song X, Zhang L, Qian Z, Jiang G. 3-Deoxyglucosone induces insulin resistance by impairing insulin signaling in HepG2 cells. Mol Med Rep. 2016;13:4506-12.
14. Liang G, Song X, Xu H, Wang F, Zhang L, Zhou L, et al. 3-Deoxyglucosone induced acute glucose intolerance in Sprague-Dawley rats: involvement of insulin resistance and impaired β-cell function. Exp Clin Endocrinol Diabetes. 2016. doi: 10.1055/s-0035-1565193.
15. Wang Q, Gr J. Effects of 3-deoxyglucosone on blood glucose of normal mice. Chin J Diabetes. 2010;18:220-2.
16. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med. 1969;123:261-6.
17. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA. 1999;96:14843-7.
18. Meier JJ. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2009;23:433-41.
19. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 1992;35:701-11.
20. Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513-48.
21. Hira T, Ikee A, Kishimoto Y, Kanahori S, Hara H. Resistant maltodextrin promotes fasting glucagon-like peptide-1 secretion and production together with glucose tolerance in rats. Br J Nutr. 2015;114:34-42.
22. Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol. 2005;185:457-65.
23. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-13.
24. Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, Hishizawa M, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig. 2010;1:56-9.
25. Legakis IN, Tzioras C, Phenekos C. Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care. 2003;26:252.
26. Zhang F, Tang X, Cao H, Lü Q, Li N, et al. Impaired secretion of total glucagon-like peptide-1 in people with impaired fasting glucose combined impaired glucose tolerance. Int J Med Sci. 2012;9:574-81.
27. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52.
28. Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, Ognibene C, et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res. 2002;34:150-4.
29. Cani PD, Holst JJ, Drucker DJ, Delzenne NM, Thorens B, Burcelin R, et al. GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol. 2007;276:18-23.
30. Kappe C, Zhang Q, Nyström T, Sjöholm A. Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetol Metab Syndr. 2014;6:70.
31. Lei L, Wang J, Zhang Z, Zhang H, Chen H, Cai D. Lipopolysaccharide-induced apoptosis in a murine intestinal endocrine cell line by modulation of Bcl-2, Baxand caspase-3. Mol Med Rep. 2013;8:1649-54.
32. Kato H, van Chuyen N, Shinoda T, Sekiya F, Hayase F. Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta. 1990;1035:71-6.
33. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 1998;47:1253-8.
34. Degen J, Beyer H, Heymann B, Hellwig M, Henle T. Dietary influence on urinary excretion of 3-deoxyglucosone and its metabolite 3-deoxyfructose. J Agric Food Chem. 2014;62:2449-56.
35. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-57.
36. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA. 2007;104:15069-74.
37. Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, Daly K, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA. 2007;104:15075-80.
38. Geraedts MC, Takahashi T, Vigues S, Markwardt ML, Nkobena A, Cockerham RE, et al. Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery. Am J Physiol Endocrinol Metab. 2012;303:E464-74.
39. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-90.
40. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes. 1998;47:632-9.
41. Murovets VO, Bachmanov AA, Travnikov SV, Churikova AA, Zolotarev VA. The involvement of the T1R3 receptor protein in the control of glucose metabolism in mice at different levels of glycemia. J Evol Biochem Physiol. 2014;50:334-44.
42. Göke B. Islet cell function: alpha and beta cells-partners towards normoglycaemia. Int J Clin Pract. 2008. doi: 10.1111/j.1742-1241.2007.01686.x.
43. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21:91-117.
44. Kjems LL, Volund A, Madsbad S. The effect of exogenous GLP-1 on the glucose mediated insulin secretion: a dose-response study in patients with type 2 diabetes mellitus and control subjects. Diabetologia. 1999;142:A39.
45. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig. 1993;91:301-7.
46. Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept. 2005;128:125-34.
47. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-37.
48. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278(1):471-8.